Kyntra Bio

Kyntra Bio is a clinical-stage biopharmaceutical company developing novel therapies for oncology and rare diseases. Its pipeline includes roxadustat for anemia associated with lower-risk myelodysplastic syndromes and FG-3246, an investigational CD46-targeted antibody-drug conjugate, plus FG-3180, a related PET imaging agent, for metastatic castration-resistant prostate cancer. The company’s mission is to advance innovative treatments through rigorous clinical development.